Menu
Search
|

Menu

Close
X

Akcea Therapeutics Inc AKCA.OQ (NASDAQ Stock Exchange Global Select Market)

31.18 USD
+0.45 (+1.46%)
As of 7:34 PM IST
chart
Previous Close 30.73
Open 30.49
Volume 4,994
3m Avg Volume 93,597
Today’s High 31.25
Today’s Low 30.49
52 Week High 33.86
52 Week Low 13.16
Shares Outstanding (mil) 66.54
Market Capitalization (mil) 1,860.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
17
FY17
52
FY16
0
FY15
0
EPS (USD)
FY18
-0.445
FY17
-3.237
FY16
-2.881
FY15
-1.214
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
78.42
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Stanley Crooke
Chairman of the Board, Since
Salary: --
Bonus: --
Sarah Boyce
President, Director, Since 2018
Salary: --
Bonus: --
Paula Soteropoulos
Chief Executive Officer, Director, Since 2018
Salary: $412,600.00
Bonus: $340,395.00
Michael Maclean
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jeffrey Goldberg
Chief Operating Officer, Since 2015
Salary: $319,982.00
Bonus: $220,788.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

55 Cambridge Pkwy Ste 100
CAMBRIDGE   MA   02142-1219

Phone: +1760.6032732
Site: akceatx.com/

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

SPONSORED STORIES